Bezard, Motac Chief Scientific Officer, holds also a position of INSERM Research Director. Bezard has authored or co-authored over 270 professional publications in the field of neurobiology, most of which are on Parkinson’s disease and related disorders. Listed in the Top 1% of the most cited neuroscientists (H factor= 76 – Google Scholar), he is known for his work on the compensatory mechanisms that mask the progression Parkinson’s disease and on the pathophysiology of levodopa-induced dyskinesia, the intimate mechanisms of cell death in Parkinson’s disease, the modelling of disease progression and the development of new strategies to alleviate symptoms and/or to slow disease progression.
Bezard is the director of a CNRS research unit located in Bordeaux, the Institute of Neurodegenerative Diseases, which features preclinical and clinical researchers working towards development of therapeutic solutions. He is also a Visiting Professor at the China Academy of Medical Sciences (Beijing, China) where he has set-up and manages a non-human primate facility dedicated to Movement Disorders. He serves on the board of international organizations such as the Michael J. Fox Foundation and Parkinson’s UK. He is Associate Editor of Neurobiology of Disease and of Synapse, two leading journals in the field. He serves on the editorial boards of several other neurobiology journals. Besides consulting for several drug companies in the field of movement disorders, he is a co-founder of Treefrog Therapeutics (France).
Motac Chief Scientific Officer